webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Dov-Val-Dil-OH TFA

  CAS No.: 133120-90-8   Cat No.: BADC-01576 4.5  

Dov-Val-Dil-OH TFA is a pharmaceutical compound whose full name is N-(2,2-dimethyl-1,3-dioxolane-4-yl)valine trifluoroacetate. It is a peptide derivative used in pharmaceutical research and development.

Dov-Val-Dil-OH TFA

Structure of 133120-90-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C24H44F3N3O7
Molecular Weight
543.63

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
(3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoic acid trifluoroacetic acid
InChI
InChI=1S/C22H43N3O5.C2HF3O2/c1-11-15(6)20(16(30-10)12-17(26)27)25(9)22(29)18(13(2)3)23-21(28)19(14(4)5)24(7)8;3-2(4,5)1(6)7/h13-16,18-20H,11-12H2,1-10H3,(H,23,28)(H,26,27);(H,6,7)/t15-,16+,18-,19-,20-;/m0./s1
InChIKey
QUIQWXWGYURKKL-NKPYJPHDSA-N
Appearance
White Solid

Dov-Val-Dil-OH TFA, also known by its full chemical name N-(2,2-dimethyl-1,3-dioxolane-4-yl)valine trifluoroacetate, is a significant compound in the realm of pharmaceutical research and development. It belongs to a class of compounds known as peptide derivatives, which are synthesized by the modification of naturally occurring peptides. Peptides themselves are short chains of amino acid monomers linked by peptide (amide) bonds. Given their mimicry of natural biological molecules, peptide derivatives like Dov-Val-Dil-OH TFA are frequently utilized in medicinal chemistry for drug development and understanding biological processes.

Peptide derivatives, including Dov-Val-Dil-OH TFA, have been increasingly utilized in the field of drug discovery due to their high specificity and potency. They can interact with a vast array of biological targets, providing a unique tool for designing drugs that might have fewer off-target effects compared to small molecules. The trifluoroacetate in Dov-Val-Dil-OH TFA serves as a counterion which can improve the compound’s solubility and stability, crucial characteristics for its storage and handling in laboratory settings. This modification may also influence how the compound interacts at the molecular level within biological systems, catering to enhanced interaction with target proteins or receptors.

The role of Dov-Val-Dil-OH TFA in drug discovery is particularly pronounced in the exploration of new therapeutic targets. In pharmaceutical research, the priority is often to identify compounds that can specifically interact with biological targets associated with disease. Peptide derivatives like Dov-Val-Dil-OH TFA can be engineered to bind selectively to such targets thanks to their tailored chemical structure, thus offering powerful scaffolds for drug design. Moreover, these compounds often exhibit minimized immunogenicity due to their peptide nature, reducing potential adverse immune responses which is a significant concern in drug development.

Another crucial aspect of Dov-Val-Dil-OH TFA’s application in drug discovery is its role in the lead optimization phase. After initial potential therapeutic compounds are identified, modifications are necessary to enhance certain characteristics such as efficacy, potency, safety, and pharmacokinetic properties. Through systematic structural variations, peptide derivatives like Dov-Val-Dil-OH TFA allow researchers to fine-tune these properties, optimizing the compound’s therapeutic potential and its eventual clinical success. The trifluoroacetate salt form further assists in improving pharmacokinetics by altering the compound’s absorption and distribution in the body.

Additionally, Dov-Val-Dil-OH TFA and similar compounds are valuable in the study of enzyme-substrate interactions and in the design of enzyme inhibitors. Enzymes play critical roles in numerous metabolic pathways, and their dysregulation is a common cause of diseases. By designing inhibitors based on peptide derivatives, researchers can effectively suppress pathogenic enzymatic activity, paving the way for the development of therapeutic agents to treat conditions ranging from cancer to infectious diseases. Specifically, the dioxolane moiety in Dov-Val-Dil-OH TFA derivatives might confer a competitive edge in inhibiting enzymes by mimicking natural substrates more closely, therefore achieving higher binding affinity and specificity.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Kdo Azide | 6-O-Propynyl-2'-deoxyguanosine | bisSP1 | 1-Boc-azetidine-3-yl-methanol | 11-Azidoundecanoic acid | Mal-PEG4-PFP | Azide-C2-SS-C2-biotin | 4-Maleimidobutyric acid | MC-Gly-Gly-{D-Phe}-Gly-NH-CH2-O-CH2COOH | Boc-L-Tyr(2-azidoethyl)-OH | Dov-Val-Dil-OH TFA
Send Inquiry
Verification code
Inquiry Basket